Angiotensin 1-7 as Means to Prevent the Metabolic Syndrome
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
We studied the effects of chronic angiotensin 1-7 (Ang 1-7) treatment in an experimental model of the metabolic syndrome, i.e., rats given high-fructose/low-magnesium diet (HFrD). Rats were fed on HFrD for 24 weeks with and without Ang 1-7 (576 µg/kg/day, s.c., Alzet pumps). After 6 months, Ang 1-7–treated animals had lower body weight (−9.5%), total fat mass (detected by magnetic resonance imaging), and serum triglycerides (−51%), improved glucose tolerance, and better insulin sensitivity. Similar metabolic effects were also evident, albeit in the absence of weight loss, in rats first exposed to HFrD for 5 months and then subjected to short-term (4 weeks) treatment with Ang 1-7. Six months of Ang 1-7 treatment were associated with lower plasma renin activity (−40%) and serum aldosterone (−48%), less hepatosteatatitis, and a reduction in epididymal adipocyte volume. The marked attenuation of macrophage infiltration in white adipose tissue (WAT) was associated with reduced levels of the pP65 protein in the epididymal fat tissue, suggesting less activation of the nuclear factor-κB (NFκB) pathway in Ang 1-7–treated rats. WAT from Ang 1-7–treated rats showed reduced NADPH-stimulated superoxide production. In single muscle fibers (myofibers) harvested and grown ex vivo for 10 days, myofibers from HFrD rats gave rise to 20% less myogenic cells than the Ang 1-7–treated rats. Fully developed adipocytes were present in most HFrD myofiber cultures but entirely absent in cultures from Ang 1-7–treated rats. In summary, Ang 1-7 had an ameliorating effect on insulin resistance, hypertriglyceridemia, fatty liver, obesity, adipositis, and myogenic and adipogenic differentiation in muscle tissue in the HFrD rats.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Kanda, H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26498 · Cited by 2,682
Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB
Cai, D., Yuan, M., Frantz, D. F., Melendez, P. A., Hansen, L., Lee, J., & Shoelson, S. E. (2005) · Nature Medicine · doi:10.1038/nm1166 · Cited by 2,245
CCR2 modulates inflammatory and metabolic effects of high-fat feeding
Weisberg, S. P., Hunter, D., Huber, R., Lemieux, J., Slaymaker, S., Vaddi, K., Charo, I., Leibel, R. L., & Jr., A. W. F. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24335 · Cited by 1,497
Insulin Resistance in Morbid Obesity
Greco, A. V., Mingrone, G., Giancaterini, A., Manco, M., Morroni, M., Cinti, S., Granzotto, M., Vettor, R., Camastra, S., & Ferrannini, E. (2002) · Diabetes · doi:10.2337/diabetes.51.1.144 · Cited by 442 · cited 2×
“Skeletal muscles are lost in diabetic patients (8), possibly due to local accumulation of adipocytes that potentially replace muscle cells (9).”
BackgroundPrevalence and Characteristics of the Metabolic Syndrome in Primary Aldosteronism
Fallo, F., Veglio, F., Bertello, C., Sonino, N., Della Mea, P., Ermani, M., Rabbia, F., Federspil, G., & Mulatero, P. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1733 · Cited by 372 · cited 1×
“The prevalence of the MetSyn is higher in patients with primary hyperaldosteronism than in essential hypertension (47).”
BackgroundThe metabolic syndrome: role of skeletal muscle metabolism.
Stump, C. S., Henriksen, E. J., Wei, Y., & Sowers, J. R. (2006) · Annals of Medicine · doi:10.1080/07853890600888413 · Cited by 362 · cited 1×
“The reninangiotensin system may also be involved in hepatic inflammation and fibrogenesis (5) and to adversely affect insulin-mediated glucose uptake in skeletal muscles (6).”
BackgroundPedersen, M., Bruunsgaard, H., Weis, N., Hendel, H. W., Andreassen, B. U., Eldrup, E., Dela, F., & Pedersen, B. K. (2003) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(03)00027-7 · Cited by 342
Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance
Cooper, S. A., Whaley-Connell, A., Habibi, J., Wei, Y., Lastra, G., Manrique, C., Stas, S., & Sowers, J. R. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00522.2007 · Cited by 317 · cited 1×
“Moreover, aldosterone, through nongenomic actions, can interfere with intracellular insulin signaling and lead to impaired glucose homeostasis and systemic insulin resistance in skeletal muscle, liver, and cardiovascular tissue (48).”
BackgroundSeppala-Lindroos, A. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.7.3023 · Cited by 168
Adiposopathy: treating pathogenic adipose tissue to reduce cardiovascular disease risk
Bays, H., Rodbard, H. W., Schorr, A. B., & González-Campoy, J. M. (2007) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-007-0021-6 · Cited by 36 · cited 1×
“Diabetes 62:1121–1130, 2013 The metabolic syndrome (MetSyn) encompasses cardiometabolic risk determinants including visceral obesity, insulin resistance, glucose intolerance, dyslipidemia, nonalcoholic fatty liver disease, and hypertension (1).”
Background
Cited by
The ACE2/angiotensin-(1-7)/MAS Axis of the renin-angiotensin system: focus on angiotensin-(1-7)
Santos, R. A. S., Sampaio, W. O., Alzamora, A. C., Motta-Santos, D., Alenina, N., Bader, M., & Campagnole-Santos, M. J. (2018) · Physiological Reviews · doi:10.1152/physrev.00023.2016 · Cited by 1,144
Skeletal muscle inflammation and insulin resistance in obesity
Wu, H., & Ballantyne, C. M. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88880 · Cited by 695
Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets
Jiang, F., Yang, J., Zhang, Y., Dong, M., Wang, S., Zhang, Q., Liu, F. F., Zhang, K., & Zhang, C. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.59 · Cited by 426
Patel, V. B., Mori, J., McLean, B. A., Basu, R., Das, S. K., Ramprasath, T., Parajuli, N., Penninger, J. M., Grant, M. B., Lopaschuk, G. D., et al. (2016) · Diabetes · doi:10.2337/db15-0399 · Cited by 255
Prokudina, E. S., Maslov, L. N., Ivanov, V. V., Bespalova, I. D., Pismennyi, D. S., & Voronkov, N. S. (2017) · Annals of the Russian academy of medical sciences · doi:10.15690/vramn798 · Cited by 17
Metadata
- Authors
- Marcus, Y., Shefer, G., Sasson, K., Kohen, F., Limor, R., Pappo, O., Nevo, N., Biton, I., Bach, M., Berkutzki, T., Fridkin, M., Benayahu, D., Shechter, Y., & Stern, N.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2013-03-14
- Volume
- 62
- Issue
- 4
- Pages
- 1121-1130
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2166530980
- Cited by
- 75
- References
- 11
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.